Zai Lab is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies primarily for patients in China and broader Asia. It builds its portfolio through in-licensing global assets and advancing its own discovery programs across oncology, autoimmune disease, infectious disease and neuroscience. The model combines late-stage development and local commercialization with regional regulatory and market expertise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 110 | — | -40.7 | — |
| Q3 2025 | 116.1 | — | -36 | — |
| Q4 2025 | 127.6 | — | -50.4 | — |
| Q1 2026 | 99.6 | — | -51 | — |
| Q2 2026 | 106.3 | -3.3% | -50.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: People Incorporated (PPLI), Digi International Inc. (DGII), Maravai LifeSciences Holdings, Inc. (MRVI), Alarm.com Holdings, Inc. (ALRM), NetScout Systems, Inc. (NTCT), Alumis Inc. (ALMS)